Regeneron Faces Securities Class Action Over Failed Melanoma Trial
Regeneron Pharmaceuticals (NASDAQ: REGN) is facing a securities class action lawsuit following the failure of its Phase 3 clinical trial for Fianlimab in combination with Libtayo to meet its primary endpoint. The company had previously expressed optimism about the treatment's potential, but investors are now alleging misleading statements and lack of transparency regarding the study’s progress. The lawsuit claims that Regeneron failed to disclose critical issues such as flawed statistical assumptions and slow event rates during the trial period from August 1, 2025, through May 15, 2026. On April 29, 2026, Regeneron announced a protocol change due to low event numbers, which was later revealed in early May as having occurred months earlier. The market reacted sharply after the trial results were disclosed on May 15, leading to an $11 billion drop in Regeneron's market capitalization. Hagens Berman is representing investors and seeking lead plaintiffs by September 14, 2026.
Tickers: $REGN
Topics: clinical_trials investor_fraud pharmaceuticals stock_price_drop